Search

Your search keyword '"Fransen, Marieke F"' showing total 218 results

Search Constraints

Start Over You searched for: Author "Fransen, Marieke F" Remove constraint Author: "Fransen, Marieke F"
Sorry, I don't understand your search. ×
218 results on '"Fransen, Marieke F"'

Search Results

1. Real‐time analysis of the cancer genome and fragmentome from plasma and urine cell‐free DNA using nanopore sequencing

2. Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors

7. Multi-modal cell-free DNA genomic and fragmentomic patterns enhance cancer survival and recurrence analysis

8. Supplementary Figures from A Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell–Mediated Immune Response against EGFR-Expressing Tumors

9. Data from A Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell–Mediated Immune Response against EGFR-Expressing Tumors

10. Supplementary Tables from A Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell–Mediated Immune Response against EGFR-Expressing Tumors

11. A Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell–Mediated Immune Response against EGFR-Expressing Tumors

15. Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors

21. Supplementary figures S1-S5 from Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy

22. Supplementary table 1 and 2 from Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy

26. Local delivery of low-dose anti–CTLA-4 to the melanoma lymphatic basin leads to systemic T reg reduction and effector T cell activation

30. Genome-wide cell-free DNA termini in patients with cancer

32. Targeting Endoglin Expressing Cells in the Tumor Microenvironment Does Not Inhibit Tumor Growth in a Pancreatic Cancer Mouse Model

33. Local delivery of low-dose anti–CTLA-4 to the melanoma lymphatic basin leads to systemic Treg reduction and effector T cell activation.

36. CD40 stimulation leads to effective therapy of CD[40.sup.-] tumors through induction of strong systemic cytotoxic T lymphocyte immunity

37. Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy

38. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy

39. Comparison of the tumor microenvironments of squamous cell carcinoma at different anatomical locations within the upper aerodigestive tract in relation to response to ICI therapy.

40. Functional diversification of hybridoma-produced antibodies by CRISPR/HDR genomic engineering

41. FcγR interaction is not required for effective anti-PD-L1 immunotherapy but can add additional benefit depending on the tumor model

42. Functional diversification of hybridoma-produced antibodies by CRISPR/HDR genomic engineering

43. Functional diversification of hybridoma-produced antibodies by CRISPR/HDR genomic engineering

44. A Dual-Color Bioluminescence Reporter Mouse for Simultaneous in vivo Imaging of T Cell Localization and Function

45. A Restricted Role for FcγR in the Regulation of Adaptive Immunity

46. Functional diversification of hybridoma produced antibodies by CRISPR/HDR genomic engineering

50. Self-Assembling Peptide Epitopes as Novel Platform for Anticancer Vaccination

Catalog

Books, media, physical & digital resources